"
Team:TU-Eindhoven/PBPK
From 2013.igem.org
(Difference between revisions)
| Line 4: | Line 4: | ||
=Ganciclovir Distribution= | =Ganciclovir Distribution= | ||
{{:Team:TU-Eindhoven/Template:Lead}} | {{:Team:TU-Eindhoven/Template:Lead}} | ||
| - | Ganciclovir is the prodrug to kill the bacteria. See the principle of killing:(). The bacteria needs to be killed at a mild rate. So it is important to predict the concentration of ganciclovir in the body, especially in the tumor zone. In this part we used '''Physiologically based pharmacokinetic model''' to describe the distribution of the drug in different tissues of body. | + | Ganciclovir is the prodrug to kill the bacteria. See the principle of killing:(). The bacteria needs to be killed at a mild rate. So it is important to predict the concentration of ganciclovir in the body, especially in the tumor zone. In this part we used '''Physiologically based pharmacokinetic model'''(PBPK) to describe the distribution of the drug in different tissues of body. |
{{:Team:TU-Eindhoven/Template:LeadEnd}} | {{:Team:TU-Eindhoven/Template:LeadEnd}} | ||
Revision as of 11:47, 6 September 2013
Contents |
Ganciclovir Distribution
Ganciclovir is the prodrug to kill the bacteria. See the principle of killing:(). The bacteria needs to be killed at a mild rate. So it is important to predict the concentration of ganciclovir in the body, especially in the tumor zone. In this part we used Physiologically based pharmacokinetic model(PBPK) to describe the distribution of the drug in different tissues of body.
Killing Mechanism
The scheme of killing mechanism is shown below.
Pharmacokinetic Model
The pharmacokinetic model is a useful tool to predict drug concentrations in human tissues. The essence of pharmacokinetic model is the *compartmental method* and the *diffusion limitation*.
References
